Deals Of The Week: Teva/Xenon, Biogen Idec/Isis, Bristol-Myers Squibb/The Medicines Company
Executive Summary
Amgen’s unexpected buyout of deCode Genetics means the founder’s expensive philosophy of focusing on pioneering science rather than quick-to-market products finally will pay off for the Icelandic firm’s venture capital backers.
You may also be interested in...
Xenon Feels No Pain After $41M Upfront From Teva
Teva and Xenon collaborate to develop the Canadian company’s lead pain product; the deal could net Xenon as much as $376 million and will fit snugly into the Israeli company’s new focus.
Biogen Idec To Collaborate With Isis On Treatment For Degenerative Muscle Disorder
The two companies build on an existing partnership in spinal muscular atrophy to address another muscle-wasting disease. For the second time, they’ve arranged an option deal, with milestones built in both before and after licensing.
Biogen Strikes A Deal With Isis For Antisense Technology
Biogen has agreed to pay an upfront and milestones for an option to license Isis' Phase I antisense compound to treat a rare spinal disorder.